by Laya Kiani | Jul 18, 2024
In last week’s post, “The role and impact of IP rights on innovation and investment in RM,” I discussed the importance of intellectual property (IP) rights in regenerative medicine (RM), highlighting how they drive innovation and secure competitive advantages....
by Laya Kiani | Jul 11, 2024
Intellectual property (IP) rights in regenerative medicine (RM) are crucial for sparking innovation and staying ahead in a competitive market. Protecting inventions through patents and other IP rights encourages investment by giving inventors exclusive market rights....
by Laine Bodnar | Jun 12, 2024
Have you wondered how many cell and gene therapies (CGTs) have been approved in Canada? So did I. To track the number down, I first turned to my trusty internet search engine with hopes that a list of Health Canada-approved CGTs would already exist online. Notably, it...
by Medicine by Design | May 6, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Medicine by Design | Apr 22, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of proflies that feature “people” of Medicine by Design. Some minor edits...
Comments